Roche Partners with Jnana Therapeutics for Immunology and Neuroscience Drugs
Roche Holding and Jnana Therapeutics have entered a partnership to discover small molecule drugs to treat immune-mediated and neurological diseases.
The molecules will target the solute carrier family of metabolite transporters, which control the movement of metabolites in and out of cell organs. The companies will work together on discovery and preclinical development of targets, which Roche will then further develop and exclusively commercialize.
Jnana will receive $40 million upfront and may receive future payments exceeding $1 billion.